Charlotte K. Hind
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Charlotte K. Hind has a total of 308 co-authors. Here are the top co-authors by number of shared publications:
- J. Mark Sutton
UK Health Security Agency
34 shared publications - Khondaker Miraz Rahman
Institute of Pharmaceutical Science, King's College London, 150 Stamford Street, London, SE1 9NH, UK
20 shared publications Melanie Clifford
Research and Evaluation, UKHSA Porton Down, Salisbury SP4 0JG, U.K.
17 shared publications- Matthew E. Wand
UK Health Security Agency
12 shared publications - Jennifer Ruth Hiscock
University of Kent, Canterbury, CT2 7NH, UK
10 shared publications - Andrew James Mason
Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Sciences, King’s College London
9 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by American Chemical Society (ACS) in ACS Chemical Biology
Genome Mining-Driven Discovery of the Sactipeptide Smithiosin in Probiotic, Thermophilic Strain Bacillus smithii
Sactipeptides are a class of ribosomally synthesised and post-translationally modified peptides (RiPPs), which have a cyclic topology formed by unique thioether crosslinks called sactionines. Sactionines are introduced by radical S-adenosylmethionine (rSAM) enzymes between cysteine residues and the α-carbon of other amino acids. Genome sequencing has revealed many putative sactipeptide biosynthetic gene clusters; however, few sactipeptides have been isolated and characterised. Here, we use genome mining to identify a novel sactipeptide from Bacillus smithii. The novel sactipeptide, named smithiosin, was extracted from the industrially important thermophile B. smithii and characterised as a novel homologue of the previously characterised sactipeptide subtilosin A from B. subtilis. Furthermore, the smithiosin precursor peptide gene was heterologously expressed in the subtilosin A producer Bacillus subtilis 168 without knockout of the native precursor peptide, successfully leading to the production of both subtilosin A and smithiosin. This demonstrates for the first time that a non-native precursor peptide is able to outcompete the subtilosin A precursor for all of the native biosynthetic enzymes in B. subtilis, including the radical SAM enzyme AlbA. It also opens a potential new opportunity for screening non-native precursor peptides with the subtilosin A biosynthetic enzymes via heterologous expression in B. subtilis.
- 5 November 2026
- Published by American Chemical Society (ACS) in ACS Chemical Biology
Open AccessGenome Mining-Driven Discovery of the Sactipeptide Smithiosin in Probiotic, Thermophilic Strain Bacillus smithii
Sactipeptides are a class of ribosomally synthesised and post-translationally modified peptides (RiPPs), which have a cyclic topology formed by unique thioether crosslinks called sactionines. Sactionines are introduced by radical S-adenosylmethionine (rSAM) enzymes between cysteine residues and the α-carbon of other amino acids. Genome sequencing has revealed many putative sactipeptide biosynthetic gene clusters; however, few sactipeptides have been isolated and characterised. Here, we use genome mining to identify a novel sactipeptide from Bacillus smithii. The novel sactipeptide, named smithiosin, was extracted from the industrially important thermophile B. smithii and characterised as a novel homologue of the previously characterised sactipeptide subtilosin A from B. subtilis. Furthermore, the smithiosin precursor peptide gene was heterologously expressed in the subtilosin A producer Bacillus subtilis 168 without knockout of the native precursor peptide, successfully leading to the production of both subtilosin A and smithiosin. This demonstrates for the first time that a non-native precursor peptide is able to outcompete the subtilosin A precursor for all of the native biosynthetic enzymes in B. subtilis, including the radical SAM enzyme AlbA. It also opens a potential new opportunity for screening non-native precursor peptides with the subtilosin A biosynthetic enzymes via heterologous expression in B. subtilis.
- Open Access
A panel of genotypically and phenotypically characterised WHO priority Gram-negative bacteria to facilitate antimicrobial and diagnostic development
Background: Antimicrobial-resistant Gram-negative bacteria pose a major threat to global health. In the WHO Bacterial Priority Pathogen List (BPPL) 2024, several species were classified as ‘critical’ or ‘high’ priority for research and development of new antimicrobial therapeutics and diagnostics. However, access to well-characterised and clinically relevant bacterial isolate panels remains an unmet need for development and validation. Methods: We constructed five panels of Gram-negative bacterial isolates, cultured from samples originally referred to the UK Health Security Agency Antimicrobial Resistance and Healthcare-Associated Infections Reference Unit for analysis between 2014 and 2025. For each isolate, antimicrobial susceptibilities were determined against a range of clinically relevant antibiotics, including third-generation cephalosporins, carbapenems, colistin and other ‘last-line’ antibiotics. WGS was performed on all isolates, and previously described resistance determinants were characterised. Results: The five panels consist of 145 isolates and represent 81 sequence types across Escherichia coli (30 isolates), Klebsiella pneumoniae (30 isolates), carbapenem-resistant Acinetobacter baumannii (30 isolates), carbapenem-resistant Pseudomonas aeruginosa (30 isolates), and a mixed panel of other healthcare-associated Enterobacterales species (25 isolates). Panels are highly representative of globally relevant strains, including those currently in circulation and on the WHO BPPL 2024, and of resistance mechanisms of public health importance. Conclusion: The panels provide a diverse, comprehensive set of multidrug-resistant Gram-negative bacterial isolates, representative of strains currently in circulation globally. Selected isolates carry a breadth of important resistance mechanisms and are highly relevant to the current epidemiological landscape. The isolates and associated metadata are available to industry, academia, and other laboratories for use in developing novel antimicrobial compounds and diagnostic assays.
Open AccessA panel of genotypically and phenotypically characterised WHO priority Gram-negative bacteria to facilitate antimicrobial and diagnostic development
Background: Antimicrobial-resistant Gram-negative bacteria pose a major threat to global health. In the WHO Bacterial Priority Pathogen List (BPPL) 2024, several species were classified as ‘critical’ or ‘high’ priority for research and development of new antimicrobial therapeutics and diagnostics. However, access to well-characterised and clinically relevant bacterial isolate panels remains an unmet need for development and validation. Methods: We constructed five panels of Gram-negative bacterial isolates, cultured from samples originally referred to the UK Health Security Agency Antimicrobial Resistance and Healthcare-Associated Infections Reference Unit for analysis between 2014 and 2025. For each isolate, antimicrobial susceptibilities were determined against a range of clinically relevant antibiotics, including third-generation cephalosporins, carbapenems, colistin and other ‘last-line’ antibiotics. WGS was performed on all isolates, and previously described resistance determinants were characterised. Results: The five panels consist of 145 isolates and represent 81 sequence types across Escherichia coli (30 isolates), Klebsiella pneumoniae (30 isolates), carbapenem-resistant Acinetobacter baumannii (30 isolates), carbapenem-resistant Pseudomonas aeruginosa (30 isolates), and a mixed panel of other healthcare-associated Enterobacterales species (25 isolates). Panels are highly representative of globally relevant strains, including those currently in circulation and on the WHO BPPL 2024, and of resistance mechanisms of public health importance. Conclusion: The panels provide a diverse, comprehensive set of multidrug-resistant Gram-negative bacterial isolates, representative of strains currently in circulation globally. Selected isolates carry a breadth of important resistance mechanisms and are highly relevant to the current epidemiological landscape. The isolates and associated metadata are available to industry, academia, and other laboratories for use in developing novel antimicrobial compounds and diagnostic assays.
- Open Access
- 1 September 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (9) , 4298-4311
Design, synthesis, and biological evaluation of azole antifungals against multidrug-resistant Candida auris
Invasive fungal infections cause over one million deaths annually, and the emerging multidrug-resistant pathogen Candida auris presents a major therapeutic challenge.
- 1 September 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (9) , 4298-4311
Open AccessDesign, synthesis, and biological evaluation of azole antifungals against multidrug-resistant Candida auris
Invasive fungal infections cause over one million deaths annually, and the emerging multidrug-resistant pathogen Candida auris presents a major therapeutic challenge.
- Open Access
- 14 July 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
Strathclyde Minor Groove Binders Bearing Amidine Tail Groups are Effective against Gram-Positive Bacterial Pathogens.
The rise of multidrug-resistant Gram-positive pathogens necessitates new antibacterial agents with mechanisms that are distinct from those of existing therapies. Here, we report the antibacterial activity and mechanistic characterization of two Strathclyde minor groove binders (S-MGBs), S-MGB-234 and S-MGB-235, synthetic DNA binding molecules designed to disrupt essential bacterial processes. These compounds displayed potent in vitro activity against clinically relevant Gram-positive pathogens, including Staphylococcus aureus and Enterococcusspp. However, potency was less pronounced against Enterococcus faecalis. Activity was retained against drug-resistant strains, and reduced susceptibility emerged more slowly during serial passaging than that observed for gentamicin under the conditions tested. Whole-genome sequencing of reduced susceptibility mutants did not identify mutations in canonical DNA targets but instead revealed recurring changes in genes associated with the cell envelope, including norA, fmtA, and cozEb, suggesting that envelope-mediated effects influence compound access rather than direct target modification. Biophysical assays demonstrate strong interactions with AT-rich oligonucleotides and gDNA, consistent with the DNA binding properties previously reported for the S-MGB class. Together, these findings demonstrate that S-MGBs represent a promising class of DNA-targeting antibacterials and provide initial evidence that reduced susceptibility emerges through heterogeneous mechanisms that do not involve obvious modifications of DNA targets.
- 14 July 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
Open AccessStrathclyde Minor Groove Binders Bearing Amidine Tail Groups are Effective against Gram-Positive Bacterial Pathogens.
The rise of multidrug-resistant Gram-positive pathogens necessitates new antibacterial agents with mechanisms that are distinct from those of existing therapies. Here, we report the antibacterial activity and mechanistic characterization of two Strathclyde minor groove binders (S-MGBs), S-MGB-234 and S-MGB-235, synthetic DNA binding molecules designed to disrupt essential bacterial processes. These compounds displayed potent in vitro activity against clinically relevant Gram-positive pathogens, including Staphylococcus aureus and Enterococcusspp. However, potency was less pronounced against Enterococcus faecalis. Activity was retained against drug-resistant strains, and reduced susceptibility emerged more slowly during serial passaging than that observed for gentamicin under the conditions tested. Whole-genome sequencing of reduced susceptibility mutants did not identify mutations in canonical DNA targets but instead revealed recurring changes in genes associated with the cell envelope, including norA, fmtA, and cozEb, suggesting that envelope-mediated effects influence compound access rather than direct target modification. Biophysical assays demonstrate strong interactions with AT-rich oligonucleotides and gDNA, consistent with the DNA binding properties previously reported for the S-MGB class. Together, these findings demonstrate that S-MGBs represent a promising class of DNA-targeting antibacterials and provide initial evidence that reduced susceptibility emerges through heterogeneous mechanisms that do not involve obvious modifications of DNA targets.
- Open Access
- 29 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (11) , 13071-13098
Designing Antibiotics with Inherent Resistance to Efflux as a Strategy to Revive Discovery against Multidrug-Resistant Pathogens
We report a novel Efflux Resistance Breaker (ERB) strategy for designing antibiotics intrinsically resistant to efflux, using fluoroquinolones as a model class. ERB-modified fluoroquinolones showed enhanced intracellular accumulation and markedly improved antibacterial activity, with up to 512-fold reduction in MIC (MIC90 0.03–2 μg/mL) across multidrug-resistant bacteria. Lead compounds KSN-L22 (46) and BL-7 (50) demonstrated potent activity against MRSA, Streptococcus pneumoniae (including MDR and PRSP), Enterococcus faecalis and E. faecium (VanA, VanB and VanD), as well as Acinetobacter baumannii and Escherichia coli. The compounds inhibited both wild-type and S84L mutant DNA gyrase (IC50 ∼ 3.8 μg/mL) and achieved a > 4-log bacterial load reduction in a murine thigh infection model at oral doses of 50 mg/kg. Favorable oral and intravenous PK/PD profiles, absence of toxicity at 1200 mg/kg/day, and no hERG, CYP450, or off-target liabilities were observed. ERB technology provides a promising strategy for designing antibiotics that are intrinsically less susceptible to efflux.
- 29 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (11) , 13071-13098
Open AccessDesigning Antibiotics with Inherent Resistance to Efflux as a Strategy to Revive Discovery against Multidrug-Resistant Pathogens
We report a novel Efflux Resistance Breaker (ERB) strategy for designing antibiotics intrinsically resistant to efflux, using fluoroquinolones as a model class. ERB-modified fluoroquinolones showed enhanced intracellular accumulation and markedly improved antibacterial activity, with up to 512-fold reduction in MIC (MIC90 0.03–2 μg/mL) across multidrug-resistant bacteria. Lead compounds KSN-L22 (46) and BL-7 (50) demonstrated potent activity against MRSA, Streptococcus pneumoniae (including MDR and PRSP), Enterococcus faecalis and E. faecium (VanA, VanB and VanD), as well as Acinetobacter baumannii and Escherichia coli. The compounds inhibited both wild-type and S84L mutant DNA gyrase (IC50 ∼ 3.8 μg/mL) and achieved a > 4-log bacterial load reduction in a murine thigh infection model at oral doses of 50 mg/kg. Favorable oral and intravenous PK/PD profiles, absence of toxicity at 1200 mg/kg/day, and no hERG, CYP450, or off-target liabilities were observed. ERB technology provides a promising strategy for designing antibiotics that are intrinsically less susceptible to efflux.
- Open Access
- 28 April 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (18) , 26382-26392
Novel Fluorinated Chlorhexidine Analogues Overcome Resistance in Gram-Negative Bacteria
Antimicrobial resistance (AMR) is a critical global health challenge that compromises the effectiveness of widely used biocides such as chlorhexidine (CHX). The emergence of CHX-resistant bacterial strains, often mediated by efflux mechanisms and membrane adaptations, necessitates the development of new chemical entities capable of overcoming these resistance pathways. Here, we report the rational design, synthesis, and biological evaluation of structurally modified CHX analogues. These analogues were designed by substituting the terminal chlorophenyl rings of CHX with strategically selected aromatic groups bearing fluorine and methyl substituents to enhance membrane permeability, modulate physicochemical properties, and reduce efflux susceptibility. A library of 13 compounds was prepared using biscyanoguanidine chemistry and aniline-based substitutions via microwave-assisted synthesis, and was fully characterized by LC–MS, HRMS, and NMR. Antibacterial activity was assessed using minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) assays against a panel of Gram-positive and Gram-negative bacteria, including CHX-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa strains harboring smvR, phoQ, and pmrB mutations. Selected analogues, particularly compounds 8 and 11, demonstrated potent antibacterial activity. Compound 11 showed MIC values predominantly in the range of 4–8 μg/mL across wild-type strains and retained activity in resistant isolates, with MIC values of 4–8 μg/mL in P. aeruginosa and 64 μg/mL in CHX-resistant K. pneumoniae. MBC values were generally comparable to MIC values for the fluorinated analogues, consistent with a biocidal mode of action, while chlorhexidine showed elevated MBC values in resistant strains. Molecular modeling suggests that these compounds form favorable interactions within hydrophobic regions of the SmvA efflux pump in K. pneumoniae, potentially reducing efflux susceptibility. Structure–activity relationship analysis highlights the importance of combining fluorine and methyl substituents to optimize physicochemical properties associated with antibacterial activity and resistance bypass. Collectively, these findings establish a foundation for the development of next-generation CHX-based biocides with improved efficacy against multidrug-resistant pathogens and support further translational evaluation.
- 28 April 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (18) , 26382-26392
Open AccessNovel Fluorinated Chlorhexidine Analogues Overcome Resistance in Gram-Negative Bacteria
Antimicrobial resistance (AMR) is a critical global health challenge that compromises the effectiveness of widely used biocides such as chlorhexidine (CHX). The emergence of CHX-resistant bacterial strains, often mediated by efflux mechanisms and membrane adaptations, necessitates the development of new chemical entities capable of overcoming these resistance pathways. Here, we report the rational design, synthesis, and biological evaluation of structurally modified CHX analogues. These analogues were designed by substituting the terminal chlorophenyl rings of CHX with strategically selected aromatic groups bearing fluorine and methyl substituents to enhance membrane permeability, modulate physicochemical properties, and reduce efflux susceptibility. A library of 13 compounds was prepared using biscyanoguanidine chemistry and aniline-based substitutions via microwave-assisted synthesis, and was fully characterized by LC–MS, HRMS, and NMR. Antibacterial activity was assessed using minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) assays against a panel of Gram-positive and Gram-negative bacteria, including CHX-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa strains harboring smvR, phoQ, and pmrB mutations. Selected analogues, particularly compounds 8 and 11, demonstrated potent antibacterial activity. Compound 11 showed MIC values predominantly in the range of 4–8 μg/mL across wild-type strains and retained activity in resistant isolates, with MIC values of 4–8 μg/mL in P. aeruginosa and 64 μg/mL in CHX-resistant K. pneumoniae. MBC values were generally comparable to MIC values for the fluorinated analogues, consistent with a biocidal mode of action, while chlorhexidine showed elevated MBC values in resistant strains. Molecular modeling suggests that these compounds form favorable interactions within hydrophobic regions of the SmvA efflux pump in K. pneumoniae, potentially reducing efflux susceptibility. Structure–activity relationship analysis highlights the importance of combining fluorine and methyl substituents to optimize physicochemical properties associated with antibacterial activity and resistance bypass. Collectively, these findings establish a foundation for the development of next-generation CHX-based biocides with improved efficacy against multidrug-resistant pathogens and support further translational evaluation.
- Open Access
- 23 March 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (4) , 2151-2156
The effects of bioisostere substitution on the antimicrobial and physicochemical properties of supramolecular self-associating amphiphiles
The use of bioisosteres enhances the antimicrobial activity for a range of supramolecular self-associating amphiphiles.
- 23 March 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (4) , 2151-2156
Open AccessThe effects of bioisostere substitution on the antimicrobial and physicochemical properties of supramolecular self-associating amphiphiles
The use of bioisosteres enhances the antimicrobial activity for a range of supramolecular self-associating amphiphiles.
- Open Access
- 10 March 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (17) , 8567-8579
Amino acid appended supramolecular self-associating amphiphiles demonstrate dual activity against both MRSA and ovarian cancer
Novel amphiphiles target cell membranes, demonstrating biological efficacy against resistant S. aureus and ovarian cancer, with strong mechanistic and DMPK evidence for future therapeutic development.
- 10 March 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (17) , 8567-8579
Open AccessAmino acid appended supramolecular self-associating amphiphiles demonstrate dual activity against both MRSA and ovarian cancer
Novel amphiphiles target cell membranes, demonstrating biological efficacy against resistant S. aureus and ovarian cancer, with strong mechanistic and DMPK evidence for future therapeutic development.
- Open Access
- 3 March 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (17) , 8580-8594
An increased throughput workflow to identify ion transport and membrane lysis agents for antimicrobial discovery
Small molecule ion transporters have shown promise as potential therapeutics for microbial infections, cancer and channelopathies. However, there are still gaps in our understanding of how ion transport function in model vesicle membranes translates to cell membranes of interest. The lipid composition of the membranes of bacterial and cancer cells differs markedly from normal human cells, yet the influence of the lipid composition on membrane function is rarely investigated – in part because of the low throughput and high cost of ion transport experiments. Here, we report an increased throughput Workflow to identify biologically relevant, pH-driven ion transport and membrane lysis pathways in vesicle membranes. We developed a set of four assays designed to report on different transport and lysis processes. We validated our assays against a panel of known transporters and produced a stepwise Workflow for the evaluation of libraries of compounds. We applied our Workflow to screen a library (Library 1) of 31 supramolecular, self-associating amphiphiles (SSAs) for transport and lysis activity in a range of vesicles with different lipid compositions, designed to mimic different types of cells, and consequently identified seven promising transporters. Antimicrobial experiments found that six of these promising transporters showed good antimicrobial activity against clinically relevant Staphylococcus aureus strains, highlighting the promise of our Workflow in identifying potential antimicrobial agents. We then applied our Workflow to investigate the ion transport and lysis properties of a second library (Library 2) of SSAs with established antimicrobial and anticancer properties, aiming to provide insight into the biological modes of action.
- 3 March 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (17) , 8580-8594
Open AccessAn increased throughput workflow to identify ion transport and membrane lysis agents for antimicrobial discovery
Small molecule ion transporters have shown promise as potential therapeutics for microbial infections, cancer and channelopathies. However, there are still gaps in our understanding of how ion transport function in model vesicle membranes translates to cell membranes of interest. The lipid composition of the membranes of bacterial and cancer cells differs markedly from normal human cells, yet the influence of the lipid composition on membrane function is rarely investigated – in part because of the low throughput and high cost of ion transport experiments. Here, we report an increased throughput Workflow to identify biologically relevant, pH-driven ion transport and membrane lysis pathways in vesicle membranes. We developed a set of four assays designed to report on different transport and lysis processes. We validated our assays against a panel of known transporters and produced a stepwise Workflow for the evaluation of libraries of compounds. We applied our Workflow to screen a library (Library 1) of 31 supramolecular, self-associating amphiphiles (SSAs) for transport and lysis activity in a range of vesicles with different lipid compositions, designed to mimic different types of cells, and consequently identified seven promising transporters. Antimicrobial experiments found that six of these promising transporters showed good antimicrobial activity against clinically relevant Staphylococcus aureus strains, highlighting the promise of our Workflow in identifying potential antimicrobial agents. We then applied our Workflow to investigate the ion transport and lysis properties of a second library (Library 2) of SSAs with established antimicrobial and anticancer properties, aiming to provide insight into the biological modes of action.
- Open Access
- 28 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (3) , 2453-2461
Idler Compounds: A Simple Protocol for Openly Sharing Fridge Contents for Cross-Screening
Academic drug discovery laboratories tend to accumulate collections of compounds with great potential value that merely reside in fridges and freezers. Cross screening these libraries against alternative targets holds significant potential for uncovering novel hits, but in the academic setting compound collections are rarely used, and shared, in this way. We present a short guide for collecting small molecules not being actively pursued in group projects (which we term "idlers") to establish an open compound library. We describe how a diverse subset of this library was screened against a panel of pathogens, with the resulting data made publicly available. We hope to encourage other academic groups to develop and share their own libraries of idlers, thereby maximizing the utility of existing resources, enabling new insights, and catalyzing novel research directions through open science.
- 28 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (3) , 2453-2461
Open AccessIdler Compounds: A Simple Protocol for Openly Sharing Fridge Contents for Cross-Screening
Academic drug discovery laboratories tend to accumulate collections of compounds with great potential value that merely reside in fridges and freezers. Cross screening these libraries against alternative targets holds significant potential for uncovering novel hits, but in the academic setting compound collections are rarely used, and shared, in this way. We present a short guide for collecting small molecules not being actively pursued in group projects (which we term "idlers") to establish an open compound library. We describe how a diverse subset of this library was screened against a panel of pathogens, with the resulting data made publicly available. We hope to encourage other academic groups to develop and share their own libraries of idlers, thereby maximizing the utility of existing resources, enabling new insights, and catalyzing novel research directions through open science.